LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

LLY

1,008.06

+2%↑

JNJ

242.47

+0.89%↑

ABBV

227.83

-0.92%↓

NVS

162.82

+1.92%↑

AZN

194.72

+0.18%↑

Home・Aandelen Lijst・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Gesloten

4.73 4.19

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.33

Max

4.79

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -7.7M
Verkoop	-10M 529K
Winstmarge	-1,463.516
Werknemers	44
EBITDA	-10M -7.7M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+54.53% upside

Dividenden
By Dow Jones
Volgende Winsten	26 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	18M 898M
Vorige openingsprijs	0.54
Vorige sluitingsprijs	4.73

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

3.255 / 3.365 Steun & Weerstand

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 mrt 2026, 18:13 UTC

Acquisities, Fusies, Overnames

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9 mrt 2026, 17:20 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9 mrt 2026, 17:15 UTC

Acquisities, Fusies, Overnames

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10 mrt 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9 mrt 2026, 23:52 UTC

Marktinformatie

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9 mrt 2026, 23:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 mrt 2026, 23:46 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Correction to Crude Prices Market Talk on March 9

9 mrt 2026, 23:42 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9 mrt 2026, 23:08 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9 mrt 2026, 23:07 UTC

Belangrijke Nieuwsgebeurtenissen

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9 mrt 2026, 21:29 UTC

Acquisities, Fusies, Overnames

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9 mrt 2026, 21:28 UTC

Acquisities, Fusies, Overnames

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9 mrt 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

9 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 mrt 2026, 20:47 UTC

Belangrijke Nieuwsgebeurtenissen

The 24 Hours When Oil Markets Went Wild -- WSJ

9 mrt 2026, 20:33 UTC

Belangrijke Nieuwsgebeurtenissen

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9 mrt 2026, 20:14 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9 mrt 2026, 19:33 UTC

Belangrijke Nieuwsgebeurtenissen

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9 mrt 2026, 19:17 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9 mrt 2026, 19:14 UTC

Marktinformatie

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9 mrt 2026, 19:00 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

9 mrt 2026, 18:23 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9 mrt 2026, 17:58 UTC

Acquisities, Fusies, Overnames

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9 mrt 2026, 17:57 UTC

Acquisities, Fusies, Overnames

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9 mrt 2026, 17:41 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9 mrt 2026, 17:41 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9 mrt 2026, 17:08 UTC

Marktinformatie

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9 mrt 2026, 17:04 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

9 mrt 2026, 17:04 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Koersdoel

By TipRanks

54.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 7 USD 54.53%

Hoogste 7 USD

Laagste 7 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arbutus Biopharma Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Arbutus Biopharma Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.